Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
10
×
Tags
biotech
10
×
boston blog main
life sciences
national blog main
san diego blog main
10
×
national top stories
new york blog main
san diego top stories
san francisco blog main
boston top stories
fda
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
ipo
cancer
biogen
gene therapy
novartis
vc
venture capital
boston
cancer immunotherapy
celgene
startups
What
ipo
10
×
bio
roundup
medicines
therapeutics
week
biotechs
company
life
million
new
public
science
biogen
companies
covid
developing
drug
dyne
firms
genetic
ipos
muscle
plans
raised
rare
sciences
years
acquisitions
activity
advance
ago
allogene
america
announced
approvals
arena’s
biology
bounty
brings
Language
unset
Current search:
biotech
×
photo
×
ipo
×
" san diego blog main "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Synthorx Files for IPO to Advance Enhanced Cytokine Drugs
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M